Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • LRRK2, 2011
    New Roles for the Parkinson's Disease Kinase LRRK2 in Cytoskeletal Dynamics

    Objective/Rationale:
    LRRK2, a key protein in Parkinson’s disease, may have a role in regulating the cytoskeleton. The cytoskeleton in nerve cells (neurons) is crucial for the growth of neuronal...

  • Therapeutics Development Initiative, 2011
    Xenon inhalation to reduce L-Dopa-induced dyskinesia

    Objective/Rationale:
    Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling levodopa-induced dyskinesia (LID) in the vast majority of...

  • Therapeutics Development Initiative, 2011
    Pharmacokinetics and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated Pre-clinical Models

    Promising Outcomes of Original Grant:
    The goal of our original project was to determine if a prodrug of acamprosate could inhibit levodopa-induced dyskinesias (LIDs) in a pre-clinical model. During...

  • LRRK2, 2011
    The Role of LRRK2 in Regulating a Calcium-Dependent Pathway Involving Lysosomal Stores and NAADP

    Objective/Rationale:
    Our preliminary evidence indicates that LRRK2 may regulate acidic calcium stores, with downstream effects on autophagy as well as a variety of other calcium dependent cellular...

  • MJFF Research Grant, 2011
    Generation of Monoclonal and Polyclonal Antibodies against LRRK1

    Objective/Rationale:
    There is great excitement that drugs targeting an enzyme called LRRK2 may have utility in the treatment of Parkinson’s disease. Some companies are attempting to develop LRRK2...

  • MJFF Research Grant, 2011
    Generation of Monoclonal and Polyclonal Antibodies Against Aggregated Forms of Alpha-Synuclein

    Objective/Rationale:
    The aggregation of alpha-synuclein plays a pivotal role in the development of Parkinson’s disease. This subproject focuses on supporting the MJFF initiative of generating...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.